Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib Vs Placebo in Patients With Stage III BRAFV600E K-Mutant Melanoma. J of Skin 2018, 2 (S1), S43. https://doi.org/10.25251/skin.2.supp.43.